YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission i...
Main Authors: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-019-13771-5 |
id |
doaj-3f80ddddea7640be87705e31f5e46a2a |
---|---|
record_format |
Article |
spelling |
doaj-3f80ddddea7640be87705e31f5e46a2a2021-05-11T09:17:19ZengNature Publishing GroupNature Communications2041-17232020-01-0111111610.1038/s41467-019-13771-5YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulationTakahiro Tsuji0Hiroaki Ozasa1Wataru Aoki2Shunsuke Aburaya3Tomoko Yamamoto Funazo4Koh Furugaki5Yasushi Yoshimura6Masatoshi Yamazoe7Hitomi Ajimizu8Yuto Yasuda9Takashi Nomizo10Hironori Yoshida11Yuichi Sakamori12Hiroaki Wake13Mitsuyoshi Ueda14Young Hak Kim15Toyohiro Hirai16Department of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto UniversityDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., LtdProduct Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., LtdDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDivision of System Neuroscience, Graduate School of Medicine, Kobe UniversityDivision of Applied Life Sciences, Graduate School of Agriculture, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityRelapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission in mice.https://doi.org/10.1038/s41467-019-13771-5 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Takahiro Tsuji Hiroaki Ozasa Wataru Aoki Shunsuke Aburaya Tomoko Yamamoto Funazo Koh Furugaki Yasushi Yoshimura Masatoshi Yamazoe Hitomi Ajimizu Yuto Yasuda Takashi Nomizo Hironori Yoshida Yuichi Sakamori Hiroaki Wake Mitsuyoshi Ueda Young Hak Kim Toyohiro Hirai |
spellingShingle |
Takahiro Tsuji Hiroaki Ozasa Wataru Aoki Shunsuke Aburaya Tomoko Yamamoto Funazo Koh Furugaki Yasushi Yoshimura Masatoshi Yamazoe Hitomi Ajimizu Yuto Yasuda Takashi Nomizo Hironori Yoshida Yuichi Sakamori Hiroaki Wake Mitsuyoshi Ueda Young Hak Kim Toyohiro Hirai YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation Nature Communications |
author_facet |
Takahiro Tsuji Hiroaki Ozasa Wataru Aoki Shunsuke Aburaya Tomoko Yamamoto Funazo Koh Furugaki Yasushi Yoshimura Masatoshi Yamazoe Hitomi Ajimizu Yuto Yasuda Takashi Nomizo Hironori Yoshida Yuichi Sakamori Hiroaki Wake Mitsuyoshi Ueda Young Hak Kim Toyohiro Hirai |
author_sort |
Takahiro Tsuji |
title |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation |
title_short |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation |
title_full |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation |
title_fullStr |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation |
title_full_unstemmed |
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation |
title_sort |
yap1 mediates survival of alk-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation |
publisher |
Nature Publishing Group |
series |
Nature Communications |
issn |
2041-1723 |
publishDate |
2020-01-01 |
description |
Relapse is a limitation for the efficacy of the anaplastic lymphoma kinase (ALK)-inhibitor alectinib in ALK-rearranged lung cancer. Here, the authors show that YAP1 activation upon alectinib treatment leads to therapy resistance and that inhibiting both YAP1 and ALK leads to longer tumor remission in mice. |
url |
https://doi.org/10.1038/s41467-019-13771-5 |
work_keys_str_mv |
AT takahirotsuji yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT hiroakiozasa yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT wataruaoki yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT shunsukeaburaya yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT tomokoyamamotofunazo yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT kohfurugaki yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT yasushiyoshimura yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT masatoshiyamazoe yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT hitomiajimizu yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT yutoyasuda yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT takashinomizo yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT hironoriyoshida yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT yuichisakamori yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT hiroakiwake yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT mitsuyoshiueda yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT younghakkim yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation AT toyohirohirai yap1mediatessurvivalofalkrearrangedlungcancercellstreatedwithalectinibviaproapoptoticproteinregulation |
_version_ |
1721450083176677376 |